[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-357274-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-357274-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","fgfr4-high-expression-is-associated-with-an-immune-responsive-phenotype-in-hccand-predicts-inferior-efficacy-of-lenvatinib-plus-pd-1-blockade","FGFR4-high expression is associated with an immune-responsive phenotype in HCCand predicts inferior efficacy of lenvatinib plus PD-1 blockade","","FGFR4-high expression is evaluated as a potential modulator of immunotherapy in advanced hepatocellular carcinoma. Motivated by LEAP-002 showing no statistically significant advantage of pembrolizumab plus lenvatinib over lenvatinib alone, the study integrates Kaplan-Meier analyses, TCGA-LIHC immune profiling, and single-cell RNA-seq to link FGFR4 levels with checkpoint programs and immune infiltration. Validation uses tumor specimens from patients receiving lenvatinib plus PD-1 inhibitors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/fgfr4-high-expression-is-associated-with-an-immune-responsive-phenotype-in-hccand-predicts-inferior-efficacy-of-lenvatinib-plus-pd-1-blockade/357274/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/fgfr4-high-expression-is-associated-with-an-immune-responsive-phenotype-in-hccand-predicts-inferior-efficacy-of-lenvatinib-plus-pd-1-blockade/357274.png","ImageObject",300,407,{"name":42,"@type":43},"4398046744996","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main motivation for studying FGFR4 expression in HCC immunotherapy?","Question",{"text":63,"@type":64},"LEAP-002 indicated that pembrolizumab plus lenvatinib did not outperform lenvatinib alone, prompting investigation of whether high FGFR4 expression could protect against or alter immunotherapy outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study evaluate the relationship between FGFR4 and immunotherapy response?",{"text":68,"@type":64},"It used Kaplan-Meier plotter for outcome associations, analyzed TCGA-LIHC for immune checkpoint gene profiles and immune cell infiltration correlations, and applied single-cell RNA-seq (GSE149614) to examine interactions between FGFR4-high and FGFR4-low cancer cell subpopulations and immune cells.",{"name":70,"@type":61,"acceptedAnswer":71},"What does FGFR4-high expression predict in patients treated with lenvatinib plus PD-1 inhibitors?",{"text":72,"@type":64},"High FGFR4 expression was linked to an immune-responsive phenotype, associated with enhanced M1 macrophage polarization and elevated PD-L1 expression, yet it also predicted inferior efficacy of lenvatinib plus PD-1 blockade.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},357274,1790634525,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":11,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":138,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":112,"preview_page_count":33,"preview_urls":144},4398046744996,"Wei et al. BMC Cancer (2026) 26:759 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16098-9](https://doi.org/10.1186/s12885-026-16098-9)  \nRESEARCH Open Access  \nFGFR4-high expression is associated with an immune-responsive phenotype in HCCand predicts inferior efficacy of lenvatinib plus PD-1 blockade  \nFuqun Wei1,2,4†, Weifu Liu3†, Zhisheng Chen2,4, Zhongwu Chen2,4* and Jingfeng Liu 1,5,6*  \nAbstract  \nBackground The LEAP-002 study showed that pembrolizumab plus lenvatinib did not provide statistically significant prognostic improvement over lenvatinib monotherapy in advanced hepatocellular carcinoma (HCC) . This study investigated the potential protective role of high fibroblast growth factor receptor 4 (FGFR4) expression, a therapeutic target of lenvatinib, in immunotherapy for HCC.  \nMethods The Kaplan Meier plotter database was used to assess the impact of FGFR4 expression on immunotherapy outcomes; theTCGA-LIHC dataset was analyzed for correlations between FGFR4 expression, immune checkpoint gene profiles, and immune cell infiltration; and single-cell RNA sequencing (scRNA-seq) data from GSE149614 were used to examine interactions between high-and low-FGFR4 cancer cell subpopulations and immune cells. Validation was performed in tumor specimens from HCC patients treated with lenvatinib in combination with PD-1 inhibitors. Results High FGFR4 expression predicted favorable immunotherapy outcomes and correlated with immune checkpoint genes such as PCDH1 and CD274, along with reduced M2 macrophage infiltration in TCGA-LIHC. scRNAseq analysis showed FGFR4 enrichment in cancer cells, with high-FGFR4 cancer cells displaying a unique CXCL1– CXCR2 signaling axis with macrophages. High FGFR4 expression activated the MAPK pathway and increased JUN(+) transcriptional activity, showing a significant positive correlation with CXCL1 levels. In HCC patients treated with lenvatinib plus PD-1 inhibitors, high FGFR4 expression was linked to enhanced M1 macrophage polarization and elevated PD-L1 expression, whereas low FGFR4 expression correlated with better clinical outcomes.  \nConclusion FGFR4-high expression is associated with an immune-responsive phenotype in HCC and predicts inferior efficacy of lenvatinib plus PD-1 blockade.  \nKeywords Hepatocellular carcinoma, FGFR4, Lenvatinib, Immunotherapy  \n†Fuqun Wei and Weifu Liu contributed equally to this work.  \n*Correspondence: Zhongwu Chen [708920855@qq.com](708920855@qq.com)[ ](708920855@qq.com)Jingfeng Liu [drjingfeng@126.com](drjingfeng@126.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nWei et al. BMC Cancer (2026) 26:759  \nIntroduction  \nImmune checkpoint inhibitors (ICIs) have shown significant therapeutic efficacy in advanced HCC, particularly when combined with tyrosine kinase inhibitors (TKIs), which can markedly enhance tr","cbCaim8gYXIORwJe","https://ap.wps.com/l/cbCaim8gYXIORwJe","pdf",7524819,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the main motivation for studying FGFR4 expression in HCC immunotherapy?\",\"answer\":\"LEAP-002 indicated that pembrolizumab plus lenvatinib did not outperform lenvatinib alone, prompting investigation of whether high FGFR4 expression could protect against or alter immunotherapy outcomes.\"},{\"question\":\"How did the study evaluate the relationship between FGFR4 and immunotherapy response?\",\"answer\":\"It used Kaplan-Meier plotter for outcome associations, analyzed TCGA-LIHC for immune checkpoint gene profiles and immune cell infiltration correlations, and applied single-cell RNA-seq (GSE149614) to examine interactions between FGFR4-high and FGFR4-low cancer cell subpopulations and immune cells.\"},{\"question\":\"What does FGFR4-high expression predict in patients treated with lenvatinib plus PD-1 inhibitors?\",\"answer\":\"High FGFR4 expression was linked to an immune-responsive phenotype, associated with enhanced M1 macrophage polarization and elevated PD-L1 expression, yet it also predicted inferior efficacy of lenvatinib plus PD-1 blockade.\"}]","FGFR4-high expression is associated with an immune-responsive phenotype in HCCand predicts inferior efficacy of lenvatinib plus PD-1 blockade | PDF",1790129529,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e42f1a79e326e0d99be83e5b5ceca1d.webp",983,1310,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/337fe8ebb9f05b3e5a3b89cfc08cba09.webp",982,1309,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e5964161cb81234475e418254d7e471.webp",981,1308,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/014d961305db05b890c1696ac1ef349e.webp",980,1306]